Key Points
- This research aims to evaluate the effects of an AT1 receptor antagonist on hypertension progression and cardiovascular health in young spontaneously hypertensive rats.
- Chronic treatment with L-158,809 (0.6 mg/kg PO) was administered from 3 to 15 weeks of age.
- The study compared the effects on spontaneously hypertensive rats and Wistar-Kyoto rats over 12 weeks with post-treatment assessments at 25 weeks.
- Blood pressure (systolic) and heart weight were measured before, during, and after treatment.
- Treatment prevented hypertension in SHR (BP 136+/-1 mm Hg vs 198+/-3 mm Hg control).
- Heart weight significantly reduced for both SHR and WKY after treatment.
- Ten weeks post-treatment, BP increased in SHR and WKY but remained lower than control values.
Structured PICO
PPopulationSpontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) starting at 3 weeks of age
IInterventionAT1 receptor antagonist (L-158,809) 0.6 mg/kg PO for 12 weeks (from 3 to 15 weeks of age)
CComparatorControl SHR and control WKY
OOutcomeSystolic blood pressure and arterial reactivitysurrogate
Early chronic treatment with an AT1 receptor antagonist in spontaneously hypertensive rats prevents hypertension development and induces persistent functional changes in arterial reactivity even after treatment withdrawal.